CAR T-Cell Therapy
The University of Chicago Medicine (UCM) has collaborated with several pharmaceutical companies on breakthrough cellular therapy clinical trials for the treatment of lymphomas and acute lymphoblastic leukemia (ALL), many of which have the potential to achieve FDA approval this year. One therapy, CAR T-Cell Therapy, genetically modifies T-cells to have chimeric antigen receptors (CARs) which allow the T-cells to recognize tumor cells. Patients will receive infusions of CAR T-cells which can recognize and kill cancer cells.
Once the treatment is approved by the FDA, UCM will be one five sites for initial commercial introduction of the new treatment protocol. UCM is building the infrastructure for the new Cellular Therapy Program which will serve as a model to help other institutions to design their own CAR T-cell therapy program.
Methods Core plays a critical role in data capture process for this new therapy. Methods core will help collect patient data through REDCap. The resulting data warehouse will serve to help refine the treatment protocols to improve treatment effectiveness.
Read more about the CAR T-cell therapy here.
Learn more about Methods Core here.